143 related articles for article (PubMed ID: 37858585)
41. Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda.
Kitonsa J; Ggayi AB; Anywaine Z; Kisaakye E; Nsangi L; Basajja V; Nyantaro M; Watson-Jones D; Shukarev G; Ilsbroux I; Robinson C; Kaleebu P
Glob Health Action; 2020 Dec; 13(1):1829829. PubMed ID: 33073737
[TBL] [Abstract][Full Text] [Related]
42. Randomized Trial of Vaccines for Zaire Ebola Virus Disease.
; Kieh M; Richert L; Beavogui AH; Grund B; Leigh B; D'Ortenzio E; Doumbia S; Lhomme E; Sow S; Vatrinet R; Roy C; Kennedy SB; Faye S; Lees S; Millimouno NP; Camara AM; Samai M; Deen GF; Doumbia M; Espérou H; Pierson J; Watson-Jones D; Diallo A; Wentworth D; McLean C; Simon J; Wiedemann A; Dighero-Kemp B; Hensley L; Lane HC; Levy Y; Piot P; Greenwood B; Chêne G; Neaton J; Yazdanpanah Y
N Engl J Med; 2022 Dec; 387(26):2411-2424. PubMed ID: 36516078
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
Henao-Restrepo AM; Longini IM; Egger M; Dean NE; Edmunds WJ; Camacho A; Carroll MW; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Hossmann S; Kondé MK; Kone S; Kuisma E; Levine MM; Mandal S; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Watson CH; Kéïta S; Kieny MP; Røttingen JA
Lancet; 2015 Aug; 386(9996):857-66. PubMed ID: 26248676
[TBL] [Abstract][Full Text] [Related]
44. Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses.
Wagstaffe HR; Clutterbuck EA; Bockstal V; Stoop JN; Luhn K; Douoguih M; Shukarev G; Snape MD; Pollard AJ; Riley EM; Goodier MR
J Clin Invest; 2020 Jul; 130(7):3936-3946. PubMed ID: 32315287
[TBL] [Abstract][Full Text] [Related]
45. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
[TBL] [Abstract][Full Text] [Related]
46. Stability and suitability for storage and distribution of Ad26.ZEBOV/MVA-BN®-Filo heterologous prime-boost Ebola vaccine.
Capelle MAH; Babich L; van Deventer-Troost JPE; Salerno D; Krijgsman K; Dirmeier U; Raaby B; Adriaansen J
Eur J Pharm Biopharm; 2018 Aug; 129():215-221. PubMed ID: 29870747
[TBL] [Abstract][Full Text] [Related]
47. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
Simon JK; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BG; Welebob C; Hanson ME; Grais RF
Vaccine; 2022 Nov; 40(46):6599-6606. PubMed ID: 36208978
[TBL] [Abstract][Full Text] [Related]
48. Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.
Ake JA; Paolino K; Hutter JN; Cicatelli SB; Eller LA; Eller MA; Costanzo MC; Paquin-Proulx D; Robb ML; Tran CL; Anova L; Jagodzinski LL; Ward LA; Kilgore N; Rusnak J; Bounds C; Badorrek CS; Hooper JW; Kwilas SA; Ilsbroux I; Anumendem DN; Gaddah A; Shukarev G; Bockstal V; Luhn K; Douoguih M; Robinson C
Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793748
[TBL] [Abstract][Full Text] [Related]
49. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
Ewer K; Rampling T; Venkatraman N; Bowyer G; Wright D; Lambe T; Imoukhuede EB; Payne R; Fehling SK; Strecker T; Biedenkopf N; Krähling V; Tully CM; Edwards NJ; Bentley EM; Samuel D; Labbé G; Jin J; Gibani M; Minhinnick A; Wilkie M; Poulton I; Lella N; Roberts R; Hartnell F; Bliss C; Sierra-Davidson K; Powlson J; Berrie E; Tedder R; Roman F; De Ryck I; Nicosia A; Sullivan NJ; Stanley DA; Mbaya OT; Ledgerwood JE; Schwartz RM; Siani L; Colloca S; Folgori A; Di Marco S; Cortese R; Wright E; Becker S; Graham BS; Koup RA; Levine MM; Volkmann A; Chaplin P; Pollard AJ; Draper SJ; Ballou WR; Lawrie A; Gilbert SC; Hill AV
N Engl J Med; 2016 Apr; 374(17):1635-46. PubMed ID: 25629663
[TBL] [Abstract][Full Text] [Related]
50. Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.
Halperin SA; Das R; Onorato MT; Liu K; Martin J; Grant-Klein RJ; Nichols R; Coller BA; Helmond FA; Simon JK;
J Infect Dis; 2019 Aug; 220(7):1127-1135. PubMed ID: 31505665
[TBL] [Abstract][Full Text] [Related]
51. Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.
Watson-Jones D; Kavunga-Membo H; Grais RF; Ahuka S; Roberts N; Edmunds WJ; Choi EM; Roberts CH; Edwards T; Camacho A; Lees S; Leyssen M; Spiessens B; Luhn K; Douoguih M; Hatchett R; Bausch DG; Muyembe JJ;
BMJ Open; 2022 Mar; 12(3):e055596. PubMed ID: 35260458
[TBL] [Abstract][Full Text] [Related]
52. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.
Regules JA; Beigel JH; Paolino KM; Voell J; Castellano AR; Hu Z; Muñoz P; Moon JE; Ruck RC; Bennett JW; Twomey PS; Gutiérrez RL; Remich SA; Hack HR; Wisniewski ML; Josleyn MD; Kwilas SA; Van Deusen N; Mbaya OT; Zhou Y; Stanley DA; Jing W; Smith KS; Shi M; Ledgerwood JE; Graham BS; Sullivan NJ; Jagodzinski LL; Peel SA; Alimonti JB; Hooper JW; Silvera PM; Martin BK; Monath TP; Ramsey WJ; Link CJ; Lane HC; Michael NL; Davey RT; Thomas SJ;
N Engl J Med; 2017 Jan; 376(4):330-341. PubMed ID: 25830322
[TBL] [Abstract][Full Text] [Related]
53. Implementing an Ebola Vaccine Study - Sierra Leone.
Widdowson MA; Schrag SJ; Carter RJ; Carr W; Legardy-Williams J; Gibson L; Lisk DR; Jalloh MI; Bash-Taqi DA; Kargbo SA; Idriss A; Deen GF; Russell JB; McDonald W; Albert AP; Basket M; Callis A; Carter VM; Ogunsanya KR; Gee J; Pinner R; Mahon BE; Goldstein ST; Seward JF; Samai M; Schuchat A
MMWR Suppl; 2016 Jul; 65(3):98-106. PubMed ID: 27387395
[TBL] [Abstract][Full Text] [Related]
54. Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.
Bockstal V; Gaddah A; Goldstein N; Shukarev G; Bart S; Luhn K; Robinson C; Anumendem D; Leyssen M; Douoguih M
NPJ Vaccines; 2021 Dec; 6(1):157. PubMed ID: 34930928
[TBL] [Abstract][Full Text] [Related]
55. Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation.
Pasin C; Balelli I; Van Effelterre T; Bockstal V; Solforosi L; Prague M; Douoguih M; Thiébaut R
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243126
[TBL] [Abstract][Full Text] [Related]
56. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
[TBL] [Abstract][Full Text] [Related]
57. The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform.
Volkmann A; Williamson AL; Weidenthaler H; Meyer TPH; Robertson JS; Excler JL; Condit RC; Evans E; Smith ER; Kim D; Chen RT;
Vaccine; 2021 May; 39(22):3067-3080. PubMed ID: 33077299
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
[TBL] [Abstract][Full Text] [Related]
59. Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Mwesigwa B; Houser KV; Hofstetter AR; Ortega-Villa AM; Naluyima P; Kiweewa F; Nakabuye I; Yamshchikov GV; Andrews C; O'Callahan M; Strom L; Schech S; Anne Eller L; Sondergaard EL; Scott PT; Amare MF; Modjarrad K; Wamala A; Tindikahwa A; Musingye E; Nanyondo J; Gaudinski MR; Gordon IJ; Holman LA; Saunders JG; Costner PJM; Mendoza FH; Happe M; Morgan P; Plummer SH; Hickman SP; Vazquez S; Murray T; Cordon J; Dulan CNM; Hunegnaw R; Basappa M; Padilla M; Gajjala SR; Swanson PA; Lin BC; Coates EE; Gall JG; McDermott AB; Koup RA; Mascola JR; Ploquin A; Sullivan NJ; Kibuuka H; Ake JA; Ledgerwood JE;
Lancet Infect Dis; 2023 Dec; 23(12):1408-1417. PubMed ID: 37544326
[TBL] [Abstract][Full Text] [Related]
60. Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study.
Puri A; Pollard AJ; Schmidt-Mutter C; Lainé F; PrayGod G; Kibuuka H; Barry H; Nicolas JF; Lelièvre JD; Sirima SB; Kamala B; Manno D; Watson-Jones D; Gaddah A; Keshinro B; Luhn K; Robinson C; Douoguih M;
Vaccines (Basel); 2024 Feb; 12(2):. PubMed ID: 38400193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
